Delcath Systems delivered the kind of quarter that resets expectations. The company reported GAAP diluted earnings of $0.17 per share against a consensus estimate calling for a $0.10 loss, a 270.0% surprise. Earnings grew 750.0% from $0.02 a year ago. Revenue of $35.1 million rose 70.7% year over year and topped the $25.63 million consensus by 37.0%. Management also raised full-year 2026 revenue guidance to $115 million to $117 million. That is the central takeaway: HEPZATO's commercial ramp is running well ahead of what the Street modeled. The tension is that the same guidance implies a sharp sequential slowdown in the fourth quarter.

The quality of the beat holds up well. HEPZATO KIT revenue reached $32.7 million, up from $19.3 million, on roughly 72% volume growth. CHEMOSAT nearly doubled to $2.4 million. Gross margin expanded to 89% from 87%. Operating income swung to $7.1 million from a small operating loss a year earlier, so the profit came from operations rather than interest income or tax items. Stock-based compensation also fell to $4.2 million from $5.6 million, which helped the GAAP line. Adjusted EBITDA more than doubled to $11.5 million, operating cash flow was $8.2 million, and cash and investments climbed to $104.3 million with no debt. There is a cost side, though. R&D rose to $11.0 million from $8.0 million and SG&A rose to $13.1 million from $10.3 million. As a result, nine-month adjusted EBITDA of $22.5 million is essentially flat with last year's $22.7 million, even though year-to-date revenue grew about 38%.

The sequential trajectory on the call was steep. Quarterly revenue has climbed from $25.0 million in the first quarter. Net income moved from a $1.1 million loss to a $7.0 million profit, and adjusted EBITDA rose from $3.4 million to $11.5 million over the same span. Management has now raised gross-margin guidance on every call, from 84%-87% at the start of the year to 87%-89% now. HEPZATO volume growth guidance went from more than 20% to at least 41%. On demand, management said that pairing or sequencing HEPZATO with systemic therapy has become the norm. It also cited:

• growing patient awareness;
• fewer competing clinical trials;
• backup treatment teams expanding capacity at centers such as MD Anderson and MGH.

The company passed its 1,000th U.S. commercial treatment. It also added AdventHealth, a 50-plus-hospital system that could serve as a referral platform, and the University of Nebraska.

Bears still have legitimate ammunition. With $89.2 million booked through nine months, the raised guide implies fourth-quarter revenue of roughly $25.8 million to $27.8 million. That is a meaningful drop from $35.1 million, which management attributes to holiday seasonality and last year's weak fourth-quarter new-patient pace. Center activations keep slipping. The year-end target has fallen from 40 to 37 to at least 36, with 33 active today. New patient starts per site have eased to about 0.6 per month from roughly 0.7-0.75 earlier in the year, though that remains above the company's 0.5 planning assumption. Revenue is also concentrated in a handful of large centers that face capacity limits. With R&D expected to keep rising into 2027, quarterly profitability may be uneven. On the pipeline side, the breast cancer trial is still enrolling slowly with no interim timing. Offsetting that:

• the colorectal interim analysis was pulled forward to mid-2027;
• a cholangiocarcinoma IND is planned for early 2027;
• an oxaliplatin-based PHP program is targeted to finish preclinical work by mid-2027;
• management views the 340B final rule as neutral to positive for pricing.

Investor sentiment improved notably heading into the report. It moved from modestly negative (-0.14) to modestly positive (+0.10), a shift from skepticism toward cautious optimism rather than enthusiasm. The stock tells a similar story. Shares closed at $14.93 before the release, up 6.4% from the open after the August report and 20% above the 200-day moving average. However, they were 14.3% below the $17.42 52-week high set just days after that report. The stock had drifted to an inter-earnings low of $13.91 on October 30, so much of the post-August enthusiasm had already been given back. The Earnings Whispers trend readings lean positive, with sequential growth and momentum improving, while AVWAP remains negative.

The bottom line is that Delcath's third quarter was a decisive beat on both lines, backed by real operating leverage, expanding margins and a sizable guidance raise. Those are not accounting artifacts. The market setup is more complicated than the surprise implies. A guided fourth-quarter step-down, slower site activation and moderating per-site starts suggest growth will be lumpier than the third quarter alone indicates. Investors will need evidence in early 2027 that the seasonal dip is temporary and that newer centers like AdventHealth can broaden a revenue base that still leans on a few large sites.